Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study

References

• Dutch colorectal cancer guideline. 2014. [cited 2020 Jan 28]. Available from: http://www.oncoline.nl/colorectaalcarcinoom
   Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. JCO. 2009;27(22):3677–3683.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. JCO. 2005;23(36):9441–9442.
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370(9582):135–142.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370(9582):143–152.
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. JCO. 2005;23(22):4866–4875.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. JCO. 2015;33(10):1112–1118.
   PubMed Web of Science ®Google Scholar
• Franken MD, van Rooijen EM, May AM, et al. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. Eur J Cancer. 2017;75:204–212.
   PubMed Web of Science ®Google Scholar
• Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol. 2017;28(6):1288–1293.
   PubMed Web of Science ®Google Scholar
• Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385(9980):1843–1852.
   PubMed Web of Science ®Google Scholar
• Razenberg LG, van Gestel YR, de Hingh IH, et al. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer. 2016;16(1):110.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Z, Barber B, et al. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin. 2011;27(1):123–130.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Pelletier E, Barber B, et al. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr Med Res Opin. 2012;28(2):221–229.
   PubMed Web of Science ®Google Scholar
• Hess GP, Wang PF, Quach D, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. JOP. 2010;6(6):301–307.
   PubMedGoogle Scholar
• McLean J, Rho YS, Kuruba G, et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15(2):135–140.
   PubMed Web of Science ®Google Scholar
• Abrams TA, Meyer G, Schrag D, et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014;106(2):djt371.
   PubMedGoogle Scholar
• Zafar SY, Marcello JE, Wheeler JL, et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. JOP. 2009;5(5):228–233.
   PubMedGoogle Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. JCO. 2008;26(10):1626–1634.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–1034.
   PubMed Web of Science ®Google Scholar
• Benson AB III, Arnoletti JP, Bekaii-Saab T, et al. Colon cancer. J Natl Compr Canc Netw. 2011;9(11):1238–1290.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Wright JD, Lim E, et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. JCO. 2013;31(28):3592–3599.
   PubMed Web of Science ®Google Scholar
• Rothwell PM. External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet. 2005;365(9453):82–93.
   PubMed Web of Science ®Google Scholar
• Mol L, Koopman M, van Gils CW, et al. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol. 2013;52(5):950–955.
   PubMed Web of Science ®Google Scholar
• Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862–870.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842–1847.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. JCO. 2012;30(6):608–615.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. JCO. 2008;26(12):2013–2019.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Bouche O, Taieb J, et al. Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018;29(1):133–138.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–1085.
   PubMed Web of Science ®Google Scholar
• Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, et al. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncol. 2018;57(2):195–202.
   PubMed Web of Science ®Google Scholar